PT - JOURNAL ARTICLE AU - Sara El Ouali AU - Jessica Philpott AU - John Vargo AU - Miguel Regueiro TI - COVID-19 in patients with IBD and pancreaticobiliary disorders AID - 10.3949/ccjm.87a.ccc062 DP - 2020 Aug 27 TA - Cleveland Clinic Journal of Medicine 4099 - http://www.ccjm.org/content/early/2020/08/25/ccjm.87a.ccc062.short 4100 - http://www.ccjm.org/content/early/2020/08/25/ccjm.87a.ccc062.full AB - Evidence shows that COVID-19 can exacerbate symptoms of inflammatory bowel disease (IBD) and pancreaticobiliary disorders, and it is important to distinguish between an IBD exacerbation and symptoms caused by COVID-19. Although IBD does not appear to increase the risk for COVID-19 or worsen outcomes, corticosteroids can increase the risk and should be avoided when treating these patients. Pancreatic and biliary disease have been described in patients with COVID-19, but it is not clear whether COVID-19 induces these diseases. For facilities resuming endoscopic procedures, there are consensus guidelines for minimizing the COVID-19 transmission risks with these procedures.